Morphological and growth alterations in Vero cells transformed by cisplatin

Cell Biology International

Volumn 30, Issue 6, 2006, Pages 485-494

  Gonçalves, Estela Maria ^a   Ventura, Cláudio Ângelo ^a   Yano, Tomomasa ^a   Rodrigues Macedo, Maria Lígia ^a,b   Genari, Selma Candelária ^a,c  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSIDADE ESTADUAL DE MATO GROSSO DO SUL   (Brazil)

^c Centro Regional Universitario de Espirito Santo do Pinhal   (Brazil)

Author keywords

Cellular transformation; Cisplatin; In vitro carcinogenesis; Vero cells

Indexed keywords

CISPLATIN;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CELL AGGREGATION; CELL GROWTH; CELL STRUCTURE; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOSKELETON; NONHUMAN; PHASE CONTRAST MICROSCOPY; SCANNING ELECTRON MICROSCOPY; TUMOR CELL; VERO CELL;

ACTINS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOGENICITY TESTS; CELL CULTURE TECHNIQUES; CELL DIVISION; CELL LINE; CELL SHAPE; CELL TRANSFORMATION, NEOPLASTIC; CERCOPITHECUS AETHIOPS; CISPLATIN; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, PHASE-CONTRAST; VERO CELLS;

EID: 33744928357     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellbi.2005.12.007     Document Type: Article

References (93)

1. Abercrombie M. Contact inhibition and malignancy. Nature 281 (1979) 259-262
2. Alitalo K., Keski-Oja J., Hedman K., and Vaheri A. Loss of different pericellular matrix components of rat cells transformed with a T-class ts mutant of Rous sarcoma virus. Virology 119 (1982) 347-357
3. Allavena P., Pirovano P., Bonazzi C., Colombo N., Mantovani A., and D'Incalci M. In vitro and in vivo effects of cisplatin on the generation of lymphokine-activated killer cells. J Natl Cancer Inst 82 (1990) 139-142
4. Badari-Osama A., Abdel N.A.B., Khalifa A.E., and Hamada F.M.A. Differential alteration of cisplatin cytotoxicity and myelotoxicity by paclitaxel vehicle cremophor EL. Naunyn Schmiedebergs Arch Pharmacol 361 (2000) 339-344
5. Bershadsky A.D., and Vasiliev J.M. Neoplastic transformations. Possible unexplored functions of cytoskeleton. In: Bershadsky A.D., and Vasiliev J.M. (Eds). Cytoskeleton (1988), Plenum Press, New York 267-283
6. Bianchi N.O., and Ayres J. Heterochromatin location on chromosomes of normal and transformed cells from African green monkey (Cercopithecus aethiops). Exp Cell Res 68 (1971) 253-258
7. Blachley J.D., and Hill J.B. Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 95 (1981) 628-632
8. Blasiak J., Kowalik J., Trzeciak A., and Wojewodzka M. Cytotoxicity and DNA damage and repair in human lymphocytes exposed to three anticancer platinum drugs. Neoplasma 46 (1999) 61-63
9. Borek C. Neoplastic transformation in vitro of a clone of adult liver epithelial cells into differentiated hepatome-like cells under conditions of nutritional stress. Proc Natl Acad Sci U S A 69 (1972) 956-959
10. Borek C., and Sachs L. In vitro cell transformation by X-irradiation. Nature 210 (1966) 276-278
11. Bridges M.A., Walker D.C., Harris R.A., Wilson B.R., and Davidson A.G. Cultured human nasal epithelial multicellular spheroids: polar cyst-like model tissues. Biochem Cell Biol 69 (1991) 102-108
12. Bristol-Myers Squibb. Platinol-AQ (cisplatin injection) prescribing information. Princeton, NJ; 1999 Oct.
13. Brown K., Quintanilla M., Ramsden M., Kerr I.B., Young S., and Balmain A. V-ras genes from Harvey and BALB murine sarcoma viruses can act as initiators of two-stage mouse skin carcinogenesis. Cell 46 (1986) 447-456
14. Canaparo R., Casale F., Muntoni E., Zara G.P., Pepa C.D., Berno E., et al. Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy. Br J Clin Pharmacol 50 (2000) 146-153
15. Carvalho C.E., Santos Jr. A.R., and Wada M.L.F. Dexamethasone-induced chromosome number alterations in cell culture. Med Sci Res 27 (1999) 219-221
16. Chambers S.K., Chopyk R.L., Chambers J.T., Schwartz P.E., and Duffy T.P. Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer. Cancer 64 (1989) 2459-2461
17. Conklin-Kenneth A. Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer 37 (2000) 1-18
18. Danesi R., De Braud F., Fogli S., De Pas T.M., Di Paolo A., Curigliano G., et al. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacol Rev 55 (2003) 57-103
19. Drewinko B., and Gottlieb J.A. Action of cis-dichlorodiammineplatinum(II) at the cellular level. Cancer Chemother Rep 59 (1975) 665-673
20. Duesberg B.H., and Vogt P.K. Differences between the ribonucleic acids of transforming and nontransforming avian tumor viruses. Proc Natl Acad Sci U S A 67 (1970) 1673-1680
21. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 2 (1990) 275-280
22. Ebert T., Bander N.H., Finstad C.L., Ramsawak R.D., and Old L.J. Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res 50 (1990) 5531-5536
23. Estacia P., Santos Jr. A.R., Moreira P.L., and Genari S.C. The cytotoxicity in Vero cells of a perfluorocarbon used in vitreoretinal surgery. Braz J Morphol Sci 19 (2002) 41-47
24. FDA - Food and Drug Administration. Prescription drug advertising: content and format for labeling of human prescription drugs. Fed Regist 44 (1979) 37434-37467
25. Genari S.C., Dolder M.A.H., and Wada M.L.F. Scanning and transmission electron microscopy of transformed Vero cells, with altered in vitro growth characteristics. J Submicrosc Cytol Pathol 28 (1996) 565-572
26. Genari S.C., Gomes L., and Wada M.L.F. Alterations in the growth and adhesion pattern of Vero cells induced by nutritional stress conditions. Cell Biol Int 22 (1998) 285-294
27. Genari S.C., and Wada M.L.F. Behavioural differences and cytogenetical analysis of a transformed cellular population derived from a Vero cell line. Cytobios 81 (1995) 17-25
28. Glück U., Kwiatkowski D.J., and Ben-Ze'ev A. Suppression of tumorigenicity in simian virus 40-transformed 3T3 cells transfected with alpha-actinin cDNA. Proc Natl Acad Sci U S A 90 (1993) 383-387
29. Goldstein R.S., and Mayor G.H. The nephrotoxicity of cisplatin. Life Sci 32 (1983) 685-690
30. Golombick T., Dansey R., Bezwoda W., and Rosendorff J. Establishment and characterization of two new human ovarian cancer cells lines UWOV1 and UWOV2 and a subline UWOV2 (Sf) growing in serum-free conditions: growth characteristics, biochemical and cytogenetic studies. In Vitro Cell Dev Biol 26 (1990) 447-454
31. Greene M.H. Is cisplatin a human carcinogen?. J Natl Cancer Inst 84 (1992) 306-312
32. Haas V.R., Santos Jr. A.R., and Wada M.L.F. Behaviour of fibroblastic cells cultured in collagen I using the sandwich technique. Cytobios 106 (2001) 255-267
33. Hansen M., Rusyn E.V., Hughes P.E., Ginsberg M.H., Cox A.D., and Willumsen B.M. R-Ras C-terminal sequences are sufficient to confer R-Ras specificity to H-Ras. Oncogene 21 (2002) 4448-4461
34. Heidelberger C., and Iype P.T. Malignant transformation in vitro by carcinogenic hydrocarbons. Science 155 (1966) 214-217
35. Hidaka S., Funakoshi T., Shimada H., Tsuruoka M., and Kojima S. Comparative effects of diethyldithiocarbamate and N-benzyl-d-glucamine dithiocarbamate on cis-diamminedichloroplatinum-induced toxicity in kidney and gastrointestinal tract in rats. J Appl Toxicol 15 (1995) 267-273
36. Huitema A.D.R., Smits K.D., Mathot R.A.A., Schellens J.H., Rodenhius S., and Beijnen J.H. The clinical pharmacology of alkylating agents in high-dose chemotherapy. Anticancer Drugs 11 (2000) 515-533
37. Howle J.A., and Gale G.R. cis-Dichlorodiammineplatinum(II): persistent and selective inhibition of deoxyribonucleic acid synthesis in vivo. Biochem Pharmacol 19 (1970) 2757-2762
38. IARC/NCI/EPA Working Group. Cellular and molecular mechanisms of cell transformation and standardization of transformation assays of established cell lines for the prediction of carcinogenic chemicals: overview and recommended protocols. Cancer Res 45 (1985) 2395-2399
39. ISO 10993-5. Biological evaluation of medical devices-Part 5: Tests for cytoxicity-in vitro methods. 1992-E.
40. Janik B., and Greco M.A. Secondary association of exogenous polynucleotides with cells and nuclei in uptake experiments. Exp Cell Res 103 (1976) 420-423
41. Johnson D.C., Luedke D.W., Sapiente R.A., and Naidu R.G. Acute lymphocytic leukemia in a male with germ cell carcinoma. A case report. Med Pediatr Oncol 8 (1980) 361-365
42. Johnson R.A., and Wichern D.W. Applied multivariate statistical analysis (1988), Prentice-Hall International p. 219-284
43. Kaiser H.E., Nasir A., Groger A.M., and Link C.J. The etiology of second primary neoplasms. In Vivo 12 (1998) 89-93
44. Leary K., and Blair C.D. Sequential events in the morphologenesis of Japanese encephalitis virus. J Ultrastruct Res 72 (1980) 123-129
45. Leopold W.R., Miller E.C., and Miller J.A. Carcinogenicity of antitumor cis-platinum(II) coordination complexes in the mouse and rat. Cancer Res 39 (1979) 913-918
46. Lieberthal W., Triaca V., and Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol - Ren Fluid Electrol Physiol 39 (1996) F700-F708
47. Linstead P., Jennings B., Prescott A., Hawley P., Warn R., and Gibson I. Scanning electron microscopy and the transformed phenotype. Micron Microsc Acta 19 (1988) 155-162
48. Lombello C.B., Malmonge S.M., and Wada M.L.F. Morphology of fibroblastic cells cultured on poly(HEMA-co-AA) substrates. Cytobios 101 (2000) 115-122
49. Malmonge S.M., Zavaglia C.A.C., Santos Jr. A.R., and Wada M.L.F. Avaliação da citotoxicidade de hidrogéis de poliHEMA: um estudo in vitro. Rev Bras Eng Biomed 15 (1999) 49-54
50. Mead G.M., Green J.A., Macbeth F.R., Williams C.J., Whitehouse J.M., and Buchanan R. Second malignancy after cisplatin, vinblastine, and bleomycin (PVB) chemotherapy: a case report. Cancer Treat Rep 67 (1983) 410
51. Micetich K.C., Barnes D., and Erickson L.C. Comparative study of the cytoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells. Cancer Res 45 (1985) 4043-4047
52. Mosmann T. Rapid colorimetric assay of cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 65 (1983) 55-63
53. Murakami N., Fukuchi S., Takeuchi K., Hori T., Shibamoto S., and Ito F. Antagonistic regulation of cell migration by epidermal growth factor and glucocorticoid in human gastric carcinoma cells. J Cell Physiol 176 (1998) 127-136
54. O'Neill J.P., Couch D.B., Mechanoff R., San Sebastian J.R., Brimer P.A., and Hsie A.W. A quantitative assay of mutation induction at the hypoxanthine-guanine phosphoribosyl transferase locus in Chinese hamster ovary cells (CHO/HGPRT system): utilization with a variety of mutagenic agents. Mutat Res 45 (1977) 103-109
55. Osanto S., Thijssen J.C., Woldering V.M., van Rijn J.L., Natarajan A.T., and Tates A.D. Increased frequency of chromosomal damage in peripheral blood lymphocytes up to nine years following curative chemotherapy of patients with testicular carcinoma. Environ Mol Mutagen 17 (1991) 71-78
56. Otto A.M., Muller C.S., Huff T., and Hannappel E. Chemotherapeutic drugs change actin skeleton organization and the expression of beta-thymosins in human breast cancer cells. J Cancer Res Clin Oncol 128 (2002) 247-256
57. Persky B., Meyskens F.L., and Hendriz M.J.C. Immunohistochemical and ultrastructural study of human melanoma colonies grown in soft agar. Am J Anat 184 (1989) 212-224
58. Persons D.L., Yazlovitskaya E.M., Cui W., and Pelling J.C. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 5 (1999) 1007-1014
59. Petinari L., Kohn L.K., Carvalho J.E., and Genari S.C. Cytotoxicity of tamoxifen in normal and tumoral cell lines and its ability to induce cellular transformation in vitro. Cell Biol Int 28 (2004) 531-539
60. 2): a report from the LMCE group. Prog Clin Biolog Res 271 (1988) 573-582
61. Pónten J. The relationship between in vitro transformation and tumor formation in vivo. Biochim Biophys Acta 458 (1976) 397-422
62. Rao M., Kumar M.M., and Rao M.A. In vitro and in vivo effects of phenolic antioxidants against cisplatin-induced nephrotoxicity. J Biochem 125 (1998) 383-390
63. Rao J., and Li N. Microfilament actin remodeling as a potential target for cancer drug development. Curr Cancer Drug Targets 4 (2004) 345-354
64. Reedjik J. The mechanism of action of platinum anti-cancer drugs. Pure Appl Chem 59 (1987) 181-192
65. Roberts J.J., and Pascoe J.M. Cross-linking of complementary strands of DNA in mammalian cells by antitumor platinum compounds. Nature 235 (1972) 282-284
66. Rosenberg B., Van Camp L., Trosko J.E., and Mansour V.H. Platinum compounds: a new class of potent antitumor agents. Nature 222 (1969) 385-386
67. Rozencweig M., Von Hoff D.D., Slavik M., and Muggia F.M. cis-Diamminedichloroplatinum(II): a new anticancer drug. Ann Intern Med 86 (1977) 803-812
68. Santos Jr. A.R., Barbanti S.H., Duek E.A.R., Dolder H., Wada R.S., and Wada M.L.F. Vero cell growth and differentiation on poly(l-lactic acid) membranes of different pore diameters. Artif Organs 25 (2001) 7-13
69. Santos Jr. A.R., Dolder H., and Wada M.L.F. Dexamethasone and fetal calf serum in differentiation of Vero cells cultured on type I collagen gel. J Submicrosc Cytol Pathol 35 (2003) 35-42
70. Santos Jr. A.R., and Wada M.L.F. Foetal calf serum and dexamethasone effects on Vero cell growth and differentiation. Cytobios 99 (1999) 159-171
71. Sattler M., and Salgia R. Targeting c-Kit mutations: basic science to novel therapies. Leuk Res 28 (2004) S11-S20
72. Schattschneider J., Wasner G., and Baron R. Chemotherapy induced neuropathy. Aktuel Neurol 28 (2001) 53-61
73. Schneider D.T., Hilgenfeld E., Schwabe D., Behnisch W., Zoubek A., Wessalowski R., et al. Acute myelogenous leukemia after treatment for malignant germ cell tumors in children. J Clin Oncol 17 (1999) 3226-3233
74. Seger R., and Krebs E.G. The MAPK signaling cascade. FASEB J 9 (1995) 726-735
75. Smets L.A. Cell transformation as a model for tumor induction and neoplastic growth. Biochim Biophys Acta 605 (1980) 93-111
76. Srb V., and Prochazkova J. Monitoring of effects of cis-diamminedichloroplatinum II. Part I. Cytogenetic analysis in vitro. Neoplasma 30 (1983) 463-467
77. Sridhar K.S., Ohuma T., Nieburgs H.E., Duncan R.C., and Holland J.F. Relationship between the in vitro colony growth of human tumors and cytologic diagnosis. Cancer 64 (1989) 2275-2278
78. Swenerton K., Jeffrey J., Stuart G., Roy M., Krepart G., Carmichael J., et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 10 (1992) 718-726
79. Tandon P., and Sodhi A. cis-Dichlorodiammine platinum(II) induced aberrations in mouse bone-marrow chromosomes. Mutat Res 156 (1985) 193-197
80. Takezawa T., Mori Y., Yonaha T., and Yoshizato K. Characterization of morphology and cellular metabolism during the spheroid formation by fibroblasts. Exp Cell Res 208 (1993) 430-441
81. Terzaghi-Howe M. Factors regulating the emergence of spontaneous and X-ray-induced variants in primary rat tracheal epithelial cell culture. In Vitro Cell Dev Biol 29 (1993) 120-126
82. Tominaga K., Shinkai T., Saijo N., Equchi K., Sasaki Y., Sakurai M., et al. Cytogenetic effects of multiagent chemotherapy on peripheral lymphocytes of patients with small cell lung cancer. Jpn J Cancer Res 77 (1986) 1241-1248
83. Treisman R. Regulation of transcription by MAP kinase cascades. Curr Opin Cell Biol 8 (1996) 205-215
84. Turnbull D., Popescu N.C., DiPaolo J.A., and Myhr B.C. cis-Platinum(II) diammine dichloride causes mutation, transformation, and sister-chromatid exchanges in cultured mammalian cells. Mutat Res 66 (1979) 267-275
85. Van Den Berg H.W., and Roberts J.J. Post-replication repair of DNA in Chinese hamster cells treated with cis platinum(II) diamine dichloride. Enhancement of toxicity and chromosome damage by caffeine. Mutat Res 33 (1975) 279-284
86. Van Imhoff G.W., Sleijfer D.T., Breuning M.H., Anders G.J., Mulder N.H., and Halie M.R. Acute nonlymphocytic leukemia 5 years after treatment with cisplatin, vinblastine, and bleomycin for disseminated testicular cancer. Cancer 57 (1986) 984-987
87. Vara J.A.F., Casado E., de Castro J., Cejas P., Belda-Iniesta C., and Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30 (2004) 193-204
88. Vermorken J.B., Kapteijn T.S., Hart A.A.M., and Pinedo H.M. Ototoxicity of cis-diamminedichloroplatinum(II): influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol 19 (1983) 53-58
89. Weiss R.B., and Christian M.C. New cisplatin analogues in development: a review. Drugs 46 (1993) 360-377
90. Wiencke J.K., Cervenka J., and Paulus H. Mutagenic activity of anticancer agent cis-dichlorodiammine platinum-II. Mutat Res 68 (1979) 69-77
91. Yuhong S., Raymond S., Maul C., Sachi G., and Chang D.D. Inhibition of anchorage-independent growth of transformed NIH3T3 cells by Epithelial Protein Lost in Neoplasm (EPLIN) requires localization of EPLIN to actin cytoskeleton. Mol Biol Cell 13 (2002) 1408-1416
92. Zhu H., and Gooderham N. Neoplastic transformation of human lung fibroblast MRC-5 SV2 cells induced by benzo[a]pyrene and confluence culture. Cancer Res 62 (2002) 4605-4609
93. Zoller J., Maier H., Flentje M., Born I.A., and Osswald H. The influence of cisplatin-5-fluorouracyl combination chemotherapy on malignant transformation of the epithelium of the oral-mucosa. HNO 42 (1994) 257-263